Jefferies Analyst Predicts FDA Emergency Use Nod For Veru's New COVID-19 Therapy In One Month

Despite recent investor skepticism, the Phase 3 COVID-19 results for Veru Inc's  (NASDAQ: VERU ) sabizabulin published in the New England Journal of Medicine "addressed most concerns," Jefferies  writes.  The analyst sees the data as "further derisking" Veru's COVID opportunity and reiterates a Buy rating  on the shares with a $55 price target.  The data likely signals an FDA Emergency Use Authorization in 30 days, Howerton contends. Related:   Veru Seeks FDA Emergency Use Nod For Its COVID-19 Treatment . Patients enrolled are, in fact, sicker and support ... Full story available on Benzinga.com